Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences arcus Biosciences — Total assets ($M) ($M)
Arcus Biosciences (RCUS) Form 10-Q / 10-K Balance Sheets
Latest, Q2 2026
924
Period ended Jun 30, 2026
Change on a year earlier
-14.0%
1,075 in Q2 2025
History
30 quarters
Since Q1 2019
Sources
29
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Arcus Biosciences — Total assets ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 924 | -14.0% | Arcus Biosciences (RCUS) Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 997 | -13.8% | Arcus Biosciences (RCUS) Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 1,139 | -1.0% | Arcus Biosciences (RCUS) Form 10-Q (filed 2026-08-05) ↗ |
| Q3 2025 | Sep 30, 2025 | 974 | -22.2% | Arcus Biosciences (RCUS) Form 10-Q (filed 2025-10-28) ↗ |
| Q2 2025 | Jun 30, 2025 | 1,075 | -9.4% | Arcus Biosciences (RCUS) Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 1,156 | -10.6% | Arcus Biosciences (RCUS) Form 10-Q (filed 2025-05-06) ↗ |
| Q4 2024 | Dec 31, 2024 | 1,150 | +5.0% | Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗ |
| Q3 2024 | Sep 30, 2024 | 1,252 | +5.1% | Arcus Biosciences (RCUS) Form 10-Q (filed 2024-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 1,186 | -2.8% | Arcus Biosciences (RCUS) Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2024 | Mar 31, 2024 | 1,293 | +3.1% | Arcus Biosciences (RCUS) Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 1,095 | -18.6% | Arcus Biosciences (RCUS) Form 10-K (filed 2025-02-25) ↗ |
| Q3 2023 | Sep 30, 2023 | 1,191 | -14.6% | SEC Filing ↗ |
| Q2 2023 | Jun 30, 2023 | 1,220 | -17.4% | SEC Filing ↗ |
| Q1 2023 | Mar 31, 2023 | 1,254 | -18.8% | SEC Filing ↗ |
| Q4 2022 | Dec 31, 2022 | 1,345 | -15.5% | Arcus Biosciences (RCUS) Form 10-K (filed 2024-02-21) ↗ |
| Q3 2022 | Sep 30, 2022 | 1,394 | +66.1% | SEC Filing ↗ |
| Q2 2022 | Jun 30, 2022 | 1,477 | +64.3% | SEC Filing ↗ |
| Q1 2022 | Mar 31, 2022 | 1,543 | +65.1% | SEC Filing ↗ |
| Q4 2021 | Dec 31, 2021 | 1,592 | +106.1% | SEC Filing ↗ |
| Q3 2021 | Sep 30, 2021 | 839 | +3.5% | SEC Filing ↗ |
| Q2 2021 | Jun 30, 2021 | 899 | +86.7% | SEC Filing ↗ |
| Q1 2021 | Mar 31, 2021 | 935 | +431.0% | SEC Filing ↗ |
| Q4 2020 | Dec 31, 2020 | 772 | +280.3% | SEC Filing ↗ |
| Q3 2020 | Sep 30, 2020 | 811 | +273.8% | SEC Filing ↗ |
| Q2 2020 | Jun 30, 2020 | 481 | +101.4% | SEC Filing ↗ |
| Q1 2020 | Mar 31, 2020 | 176 | -31.9% | SEC Filing ↗ |
| Q4 2019 | Dec 31, 2019 | 203 | – | SEC Filing ↗ |
| Q3 2019 | Sep 30, 2019 | 217 | – | SEC Filing ↗ |
| Q2 2019 | Jun 30, 2019 | 239 | – | SEC Filing ↗ |
| Q1 2019 | Mar 31, 2019 | 259 | – | SEC Filing ↗ |
Breakdown
What makes up arcus biosciences — total assets ($m)
- Arcus Biosciences — Cash and cash equivalents ($M)150 · Q2 2026
- Arcus Biosciences — Marketable securities, current ($M)552 · Q2 2026
- Arcus Biosciences — Unbilled receivables / contract asset from Gilead ($M)36 · Q2 2026
- Arcus Biosciences — Deferred collaboration revenue, current ($M)19 · Q2 2026
- Arcus Biosciences — Deferred collaboration revenue, noncurrent ($M)37 · Q2 2026
- Arcus Biosciences — Total current liabilities ($M)198 · Q2 2026
- Arcus Biosciences — Total liabilities (legacy XBRL tag, $M)695 · Q3 2022
Cite this data
StockData. (2026). Gilead Sciences Arcus Biosciences — Total assets ($M) ($M), quarterly Q1 2019–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rcus_assets_tot
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.